Samsung Biologics’ Plant 4 facility (courtesy Samsung)
April 24, 2024 10:55 AM EDTUpdated April 29, 04:42 AM
Manufacturing

Sam­sung Bio’s bet on Plant 4 con­tin­ues to pay off with first-quar­ter earn­ings growth

Anna Brown

News Reporter

Sam­sung Bi­o­log­ics’ Plant 4 re­mains a worth­while $2 bil­lion in­vest­ment.

The CD­MO said that the fa­cil­i­ty was key in its first-quar­ter gains and will con­tin­ue …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times